Nuvation Bio Inc. (NUVB)

Market Cap	736.57M
Revenue (ttm)	n/a
Net Income (ttm)	-68.87M
Shares Out	247.17M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,426,057
Open	3.150
Previous Close	3.160
Day's Range	2.940 - 3.200
52-Week Range	0.950 - 4.160
Beta	1.42
Analysts	Strong Buy
Price Target	6.60 (+121.48%)
Earnings Date	Aug 1, 2024

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC)...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 159
• Stock Exchange: NYSE
• Ticker Symbol: NUVB

Analyst Forecast

According to 5 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $6.6, which is an increase of 121.48% from the latest price.

Price Target

$6.6

(121.48% upside)

Analyst Consensus: Strong Buy